Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $112.17 to $115.76
• 50-Day Range: $106.12 to $118.23
• 52-Week Range: $95.49 to $148.06
• Volume: 598,949 shs
• Average Volume: 582,660 shs
• Market Capitalization: $6.99 billion
• P/E Ratio: 15.40
• Dividend Yield: N/A
• Price Target: $181.64
• Consensus Rating: Moderate Buy

Jazz Pharmaceuticals Stock Analysis - MarketRank™

Jazz Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 41st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Jazz Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.32%

Earnings Growth

Earnings for Jazz Pharmaceuticals are expected to grow by 10.32% in the coming year, from $16.96 to $18.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jazz Pharmaceuticals is 15.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jazz Pharmaceuticals is 15.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

Price to Earnings Growth Ratio

Jazz Pharmaceuticals has a PEG Ratio of 5.51. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Jazz Pharmaceuticals has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.92% of the float of Jazz Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Jazz Pharmaceuticals has recently decreased by 2.39%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jazz Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Jazz Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.96

Percentage of Shares Shorted

9.92% of the float of Jazz Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Jazz Pharmaceuticals has recently decreased by 2.39%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.12

News Sentiment

Jazz Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Jazz Pharmaceuticals this week, compared to 12 articles on an average week.

Search Interest

Only 7 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Jazz Pharmaceuticals insiders have bought 6,084.53% more of their company's stock than they have sold. Specifically, they have bought $9,992,963.00 in company stock and sold $161,580.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Jazz Pharmaceuticals is held by insiders.

Percentage Held by Institutions

89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JAZZ Stock Analysis - Frequently Asked Questions

How have JAZZ shares performed this year?

Jazz Pharmaceuticals' stock was trading at $123.15 at the beginning of 2025. Since then, JAZZ shares have decreased by 6.2% and is now trading at $115.52.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, May, 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by $2.97. The company's revenue was down .5% on a year-over-year basis.
Read the conference call transcript.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion.

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' top institutional shareholders include Swedbank AB (1.78%), Perpetual Ltd (1.47%), Polaris Capital Management LLC (1.05%) and Boston Trust Walden Corp (0.67%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Mary Elizabeth Henderson, Peter Gray, Samantha Pearce, Rick E Winningham, Patricia Carr, Mark Douglas Smith and Jennifer E Cook.
View institutional ownership trends.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:JAZZ
• CIK: 1232524
• Web: www.jazzpharma.com
• Phone: (531) 634-7800
• Fax: 353-1634-7850
• Employees: 2,800
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Jazz Pharmaceuticals: $181.64
• High Price Target: $230.00
• Low Price Target: $147.00
• Potential Upside/Downside: +57.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.50
• Trailing P/E Ratio: 15.40
• Forward P/E Ratio: 6.81
• P/E Growth: 5.51
• Net Income: $560.12 million
• Net Margins: 11.86%
• Pretax Margin: 8.91%
• Return on Equity: 26.62%
• Return on Assets: 9.14%

Debt

• Debt-to-Equity Ratio: 1.28
• Current Ratio: 3.38
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $4.07 billion
• Price / Sales: 1.72
• Cash Flow: $30.56 per share
• Price / Cash Flow: 3.78
• Book Value: $67.72 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 60,510,000
• Free Float: 57,909,000
• Market Cap: $6.99 billion
• Optionable: Optionable
• Beta: 0.34